drugset
drugset / Trial / NCT04039022

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022 ↗

Phase 3 Completed 876 enrolled Axsome Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.

Timeline

Start
2019-07-08
Primary completion
2020-10-23
Completion
2020-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule — Oral
Subject Dextromethorphan Unknown — Oral

Indications

major depressive disorder